Novo Nordisk Looks To Broaden Therapeutic Reach With Move Into ATTR

Company Acquires Phase II-Ready Prothena Drug

 
• By Alaric DeArment
  
Anatomy of Human Heart
Novo Nordisk has sought to broaden its reach beyond obesity and diabetes and move into areas like cardiology • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business